Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to $19.6 million.

  • Heron Therapeutics' Non-Current Assets fell 2360.3% to $19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.8 million, marking a year-over-year decrease of 2579.86%. This contributed to the annual value of $24.1 million for FY2024, which is 2845.67% down from last year.
  • Heron Therapeutics' Non-Current Assets amounted to $19.6 million in Q3 2025, which was down 2360.3% from $21.2 million recorded in Q2 2025.
  • Heron Therapeutics' Non-Current Assets' 5-year high stood at $51.3 million during Q4 2021, with a 5-year trough of $19.6 million in Q3 2025.
  • Over the past 5 years, Heron Therapeutics' median Non-Current Assets value was $35.9 million (recorded in 2023), while the average stood at $35.7 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first soared by 3295.21% in 2022, then plummeted by 2845.67% in 2024.
  • Quarter analysis of 5 years shows Heron Therapeutics' Non-Current Assets stood at $51.3 million in 2021, then fell by 11.25% to $45.5 million in 2022, then decreased by 25.89% to $33.7 million in 2023, then decreased by 28.46% to $24.1 million in 2024, then dropped by 18.99% to $19.6 million in 2025.
  • Its last three reported values are $19.6 million in Q3 2025, $21.2 million for Q2 2025, and $22.9 million during Q1 2025.